Erratum to A phase II study of the efficacy and safety of the MET inhibitor capmatinib (INC280) in patients with advanced hepatocellular carcinoma
Sign Up to like & getrecommendations! Published in 2020 at "Therapeutic Advances in Medical Oncology"
DOI: 10.1177/1758835920913426
Abstract: [This corrects the article DOI: 10.1177/1758835919889001.]. read more here.
Keywords: efficacy safety; safety met; study efficacy; erratum phase ... See more keywords